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Cell-based regenerative therapy is undergoing experimental and clinical trials in cardiology, in order to limit the consequences of
decreased contractile function and compliance of damaged ventricles following myocardial infarction. Over 1000 patients have
been treated worldwide with cell-based procedures for myocardial regeneration. Cellular cardiomyoplasty seems to reduce the
size and ﬁbrosis of infarct scars, limit adverse postischemic remodelling, and improve diastolic function. The development of a
bioartiﬁcial myocardium is a new challenge; in this approach, tissue-engineered procedures are associatedwith cell therapy. Organ
decellularization for bioscaﬀolds fabrication is a new investigated concept. Nanomaterials are emerging as the main candidates
to ensure the achievement of a proper instructive cellular niche with good drug release/administration properties. Investigating
the electrophysiological properties of bioartiﬁcial myocardium is the challenging objective of future research, associating a
multielectrode network to provide electrical stimulation could improve the coupling of grafted cells and scaﬀolds with host
cardiomyocytes. In summary, until now stem cell transplantation has not achieved clear hemodynamic beneﬁts for myocardial
diseases. Supported by relevant scientiﬁc background, the development of myocardial tissue engineering may constitute a new
avenue and hope for the treatment of myocardial diseases.
1.Introduction
Ischemic myocardial disease, the main cause of heart failure,
is a major public health and economic problem. Given the
aging population, heart failure is becoming a bigger clinical
issue and bigger ﬁnancial burden [1, 2]. Thus, research
in heart failure is of relevant interest and importance,
involving specialities ascellularand molecularbiology,tissue
engineering, genetics, biophysics, and electrophysiology.
2.CellularCardiomyoplasty
The recent progress in cellular and molecular biology allows
the development of new therapies for heart failure. One of
the most innovative consists in the transplantation of stem
cells into the myocardium for heart muscle regeneration.
This approach is called “cellular cardiomyoplasty” [3, 4].
Adult myocardium cannot eﬀectively repair after infarction
due to the limited number of stem cells. Thus, most of the
injury is irreversible [5]. For this reason, cell transplantation
strategies for heart failure have been designed to replace
damaged cells with cells that can induce angiogenesis in
order to recover hibernating and stunned myocardium or
to grow new ﬁbers creating contractile tissue that will
perform cardiac work, either in ischemic or nonischemic
cardiomyopathies.
Grafting of healthy cells into the diseased myocardium
holds enormous potential as an approach to cardiovascular
pathology. The functional goalo fc e l lt r a n s p l a n t a t i o ni s
to contribute to improve systolic and diastolic ventricular
functionsandtoreversethepostischemicremodelingprocess
responsible for ventricular chambers dilatation [5].
The encouraging results of experimental studies [6–10]
have opened the way to the clinical application of cellular
cardiomyoplasty in patients with akinetic and nonviable
postinfarction scar and low ejection fraction and in patients2 Cardiology Research and Practice
presenting idiopathic and chagasic cardiomyopathies [11–
14]. Cultured autologous cells do not raise immunologi-
cal, ethical, tumorogenesis, or donor availability problems.
Thus, the development of cell therapy for heart failure is
progressing according to a rigorous scientiﬁc methodology,
from observation to experimentation to a careful evaluation
of preliminary clinical results.
Current possibilities in cell therapy for myocardial
regeneration are the transplantation into the damaged
myocardium of diﬀerent types of stem cells as autolo-
gous myoblasts (originating from a skeletal muscle biopsy)
[15], bone marrow stem cells [16], peripheral blood stem
cells [17], vascular endothelial cells [18], mesothelial cells
(removed from a biopsy of the omentum) [19], adipose tis-
sue stem cells [20], umbilical cord cells, induced pluripotent
stem cells (iPSCs), and embryonic pluripotent cells [21].
There is a tendency to use bone marrow cells for myocardial
regeneration since this approach avoids the 3-week cell-
culture procedure and the risk of ventricular arrhythmias
andsuddendeathobservedafterskeletalmyoblast transplan-
tation.
Tissue engineering using biological and synthetic matrix
is now associated with cell therapy, the goal is to develop a
bioartiﬁcial myocardium [22–27]. The MAGNUM Clinical
Trial (Myocardial Assistance by Grafting a New Upgraded
bioartiﬁcial Myocardium) is under development by our
group [28].
3.Indications
3.1. Ischemic Cardiomyopathy. Clinical application for cell
transplantation should be in patients presenting a cardiac
dysfunctionduetoleftorrightventricularmyocardialinfarc-
tion. The cells are generally implanted during catheter-based
or surgical revascularization procedures. The objective of
cellular cardiomyoplasty (CMP) is to limit infarct expansion
and cardiac remodelling and regenerate the myocardium.
Patients with ischemic mitral valve regurgitation can also be
treated with stem cells [4, 29].
3.2. Nonischemic Cardiomyopathies. Non ischemic dilated
cardiomyopathies and Chagas disease are also major causes
of heart failure, with high mortality rates [2, 13]. Cell
transplantation could oﬀer new hopes in this disease by
restoring impaired heart function, since the grafted cells
appear to better survive in the host myocardium because
myocardial irrigation in these pathologies is not severely
impaired. Stem cells are injected after catheterization of
the coronary arteries. New indications include diabetic and
pediatric cardiomyopathies.
4.Mechanisms of Action
The many proposed mechanisms of action of cellular
cardiomyoplasty are reduction of the size and ﬁbrosis of
infarct scars, limitation of adverse postischemic ventricular
remodeling, improvement of ventricular wall thickening and
compliance, and increase of regional myocardial contrac-
tility. Bone marrow cells principally induce angiogenesis
and vasculogenesis. Mesenchymal bone marrow cells and
induced pluripotent stem cells (iPSCs) are of great interest,
since these cells can diﬀerentiate in cardiac cells [30].
The initial clinical trials of cell transplantation after a
myocardial infarction have reported only limited improve-
ments in ventricular function. Ongoing studies showed
survival of the implanted cells, but no study showed active
participation of the implanted cells in the force generation.
This may be due to the lack of electrophysiological connec-
tions between the implanted cells and the host myocardium
and lack of the gap junction protein (connexin 43).
In summary, the mechanisms of action of cell therapy
seem to be
(i) reduction of the size and ﬁbrosis of infarct scars,
(ii) improvement of myocardial viability,
(iii) limitation of global ventricular dilatation (positive
remodelling),
(iv) improvement of ventricular wall compliance and
diastolic function,
(v) paracrine eﬀects (antiapoptotic and angiogenic).
5.Cell Delivery
The technical approach used to implant the cells should
inﬂuence the eﬃcacy of cellular CMP. Cell mortality after
transplantation seems to be important when they are grafted
in the center of high-ﬁbrotic ischemic scars, since there are
limitations of oxygen and nutrients supply to the chronic
ischemic myocardium. Implanting the cells mainly in the
peri-infarct areas may improve the rate of surviving cells,
thus the size of the infarct scar may undergo a centripetal
reduction [4].
Periodically repeated cell injections should be neces-
sary to progressively reduce the infarct scars in ischemic
cardiomyopathies [31] or to gradually improve the dis-
eased myocardium in nonischemic cardiomyopathies. This
approach should be boosted by the development of a
new generation of speciﬁc catheters for percutaneous cell
implantations [14].
Intracoronary and endoventricular catheter-based cell
delivery procedures for therapeutic angiogenesis and myo-
genesis have been performed. Nevertheless, the quantity of
the cells injected in the target infarcted area is unknown,
despite the use of myocardial mapping to identify the
pathologic myocardium. The success is largely dependent
on many technical considerations namely the risk of cell
regurgitation at the injection site and the precise
localization of the postischemic scar and the peri-infarct
areas [14].
A new diagnostic-therapeutic device for local myocardial
treatment has been created by our group, called “CELL-FIX”
catheter [32]. This system includes a method and apparatus
to identify by electrophysiology the infarcted area and to
simultaneously deliver the cells, stabilizing by vacuum the
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fact, the Cell-Fix catheter includes a ﬁxing “sucker” system
to the endocardium, in the form of a suction cup; this
“umbrella” is retracted inside the exterior tube of the distal
part of the catheter during the introduction and progression
of the device into the arteries. Importantly, during cell
delivery the umbrella avoids the risk of ventricular wall
perforation by the catheter at the level of the myocardial
infarction. Thiscomplicationwasalready observedinclinical
cases treated with current available catheters.
Experimental studies using the Cell-Fix catheter have
demonstrated a minimal loss of the injected material in
beating hearts treated after myocardial infarction [32].
6.HypoxicPreconditioningof StemCells
Hypoxicpreconditioning ofstem cells beforetransplantation
into the infarcted heart seems to be useful to promote cell
survival and to increase their therapeutic potential. Cell
cultures can be performed under low oxygen conditions;
ﬂasks can be transferred to a hypoxic incubators (e.g., Xvivo;
Biospherix, Lacona, NY), allowing for uninterrupted cell
culture and passaging in a controlled atmosphere of 5% O2
and 5% CO2 balanced with nitrogen [33]. Under hypoxic
conditions, the cells grow faster, thus hypoxia seems to give
an initial boost followed by regular stimuli for growth.
Animal studiesdemonstrated that hypoxic precondition-
ing enhances the capacity of mesenchymal stem cells to
repair infarcted myocardium, attributable to reduced cell
death and apoptosis of implanted cells, increased angiogen-
esis/vascularization, and paracrine eﬀects [34]. In summary,
cell preconditioning using reducedoxygen tension to expand
cells in the cultures is of relevant interest for the treatment of
ischemic heart disease, since these cells could survive better
after transplantation in the ischemic myocardium.
7.Developmentof BioartiﬁcialMyocardium
The objective of cellular cardiomyoplasty is to regenerate
the myocardium by the implantation of living cells. How-
ever, in ischemic disease, the extracellular matrix is also
pathologically modiﬁed. Therefore, it could be important to
associateaprocedureaimingatregeneratingbothmyocardial
cells and the extracellular matrix. We are currently working
to evaluate the potential of a biodegradable tridimensional
matrix seeded with cells and grafted onto the infarcted
ventricle [22].
Shortly after myocardial infarction, inﬂammatory cells
such as neutrophils, monocytes, and macrophages inﬁltrate
the infarcted zone, and then the necrotic myocytes in the
injured myocardium are replaced by collagen ﬁbers. This
process uniformly occurs in the whole infarcted area and
determines the degree of early infarct expansion. Prevention
of the dilation, secondary to LV remodelling, can increase
cardiac performance [5].
There are two types of collagen ﬁbers in the normal
adult heart, types I and III, produced by ﬁbroblasts and
myoﬁbroblasts. The ﬁber type I represents 80% of collagen
protein in the heart, and type III is near to 10%. These ﬁbers
provide structural support and give the heart properties
that include stiﬀness and resistance to deformation; they
have also shown an important role as a link between
contractile elements of adjacent myocytes, carrying some
information useful for cell function. In the infarcted zone,
the extracellular myocardial matrix is modiﬁed; collagen
type I decreases from 80% to 40%. Experimental and
clinical studies performed by our group in ischemic patients
showed that bone marrow cell therapy associated with the
surgical implantation onto the epicardium of a cell-seeded
collagen type I matrix prevented myocardial wall thinning
and limited postischemic remodelling [22, 28]. In addition,
collagen matrix as a delivery vehicle signiﬁcantly reduced
the relocation of transplanted MSCs to remote organs and
noninfarcted myocardium [35].
8.ClinicalPerspectives
Followup of congestive heart failure patients has mobilized a
growing number of research teams over the past years. Med-
ical treatment particularly with ACE inhibitors combined to
beta and aldosterona blockers, heart rate reduction using
drugs like Ivabradine [36], and electrophysiological pro-
cedures like multisite pacing for atrial-biventricular resyn-
chronization and implantable deﬁbrillators have proven
to be eﬀective, improving the prognosis of heart failure
patient. However, these treatments remain palliative in many
patients, and a lot of cardiovascular diseases still evolve
towards the deﬁciency of the cardiac muscle [1].
Cardiac transplantation remains the only curative treat-
ment of congestive heart failure but has remained limited
in its application secondary to shortage of donated organs,
age of recipients, and other strict selection criteria. Surgical
alternativesforrefractory heartfailure suchasleftventricular
geometry/remodeling interventions and dynamic cardiomy-
oplasty also remain limited in their applicability as well [3,
37].Cardiomyoplasty, in which the latissimus dorsi muscleis
usedtocreateanLVwrap,hasbeenproposedbyourgroupat
theearliest80s,butnowadaysitremainsdedicatedtopatients
with right ventricular dysfunction and relatively preserved
LV function [38].
Implantable cardiac assist devices are still in evolution.
While mechanical support continues to improve, intrinsic
disadvantages remain, such as thromboembolism, the need
for careful anticoagulation, infection, lack of physiological
response, durability, and power supply [39]. Xenotransplan-
tation is in the early phase of research with no clinical
applications as of yet.
Historically, tissue regeneration techniques based in
cell transplantation technology had been used for the
treatment of hemopathies (chronic lymphocytic leukemia,
aplastic anaemia, immunodeﬁciencies, and myeloma), in
ophthalmology (transplantation of limbal stem cells for
corneal regeneration), and in orthopedics (implantation
of chondrocytes for articular defects). Current clinical
investigations concern the following specialities: endocrinol-
ogy (transplantation of stem cells in diabetes mellitus),
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(implantation of hepatocytes as a bridge to liver transplanta-
tion), myology (transplantation of myoblasts in Duchenne
dystrophy), dermatology (implantation of cultured ker-
atinocytesandﬁbroblastsinburnedpatients),andperipheral
vascular diseases (implantation of angiogenic stem cells
in critical limb ischemia). Transplanted neurally induced
embryonic stem cells can diﬀerentiate into myelin-forming
cells and provide a potential therapy for severely injured
peripheral nerves and spinal cord traumatic injury [40].
Engineered organs are in development. Regenerative
medicine uses combinations of cells and/or biomaterials
to encourage regeneration of healthy tissue and oﬀers an
alternative approach for the replacement of lost or deﬁcient
organs. Promising results have already been obtained in
urology, in children with neurogenic bladder caused by
myelomeningocele.Humanclinicaltrialsareongoinginboth
children and adults to further evaluate the safety and eﬃcacy
of this technology for regenerating bladders [41].
T h ep r e v a l e n c eo fs e v e r eh e a r tf a i l u r ea n dt h ec l e a rc l i n -
ical limitations of conventional interventions have encour-
aged the development of new methods based on the
regeneration of the pool of myocardial contractile cells.
This approach is supported by recent advances in cellular
and molecular biology. New technologies for cell implanta-
tion, derived from interventional cardiology procedures, are
emerging. Intracoronary and endoventricularcatheter-based
cell delivery for therapeutic angiogenesis and myogenesis
have been performed [14, 16, 17].
Cell transplantation is becoming recognized as a viable
strategy to improve myocardial viability and limit infarct
growth. The major challenges for future research programs
are the preconditioning for prediﬀerentiation of stem cells
before transplantation the optimization of the rate of
surviving cells after myocardial implantation associating
angiogenic therapy (growth factors and/or bone-marrow
derived cells) [42, 43] with myogenic cells (skeletal muscle
cells and bone marrow mesenchymal stem cells) [44].
The improvement of host-cell interactions (mechanical
and electrical coupling) is of great importance and interest.
To achieve this goal, we have associated electrostimulation
(cardiac resynchronization therapy) with stem cell trans-
plantation in ischemic hearts [45]. The development of a
bioartiﬁcialmyocardiumisanewchallenge;inthisapproach,
tissue engineered procedures are associated with cell therapy
[25, 27]. The preliminary results of the MAGNUM Clinical
Trial (Myocardial Assistance by Grafting a New Upgraded
bioartiﬁcial Myocardium) are encouraging [28]( Figure 1).
9.OrganDecellularizationfor
BioscaffoldFabrication
The use of synthetic and naturally-derived scaﬀolds for
bioengineering of solid organs has been limited due to a
lack of an integrated vascular network. Natural bioscaﬀolds
constitute a new approach for tissue engineering. Fabrica-
tions of a bioscaﬀold system with intact vascular tree are in
development in specialities such as hepatology, cardiology,
and ophthalmology. Animal-donor organs and tissues have
been perfused with decellularization solutions to selectively
remove the cellular component of the tissue and leave
an intact extracellular matrix and vascular network. The
vascular tree demonstrated sequential ﬂuid ﬂow through a
central inlet vessel that branched into an extensive capillary
bed and coalesced back into a single outlet vessel.
9.1. Hepatology. Human liver cells have been used to engi-
neer miniature livers. These livers successfully function in a
laboratory setting like human livers. To engineer the organ,
animal livers were treated with a mild detergent to remove
all cells; this process is called decellularization, leaving only
the collagen “skeleton” or support structure. The original
cells are then replaced with two types of cells: immature
liver cells known as progenitors and endothelial cells that
line blood vessels. The cells were introduced into the liver
skeleton through a large vessel that feeds a system of smaller
vessels in the liver. This network of vessels remains intact
after the decellularization process. The liver is next placed
in a bioreactor, a special equipment that provides a constant
ﬂow of nutrients and oxygen throughout the organ. After
a week in the bioreactor system, it was documented the
progressive formation of human liver tissue, as well as liver-
associated function. This results in a widespread cell growth
inside the bioengineered organ. The engineered organs can
be grown from the patients’ own cells, so there is no risk
of rejection. Bioengineered livers could also be useful for
evaluating the safety of new drugs; this approach would
more closely mimic drug metabolism in the human liver
[46].
9.2. Cardiology. A bioartiﬁcial heart is a theoretical alter-
native to transplantation or mechanical left ventricular
support.Generating abioartiﬁcial heart requiresengineering
of cardiac architecture, appropriate cellular constituents,
and pump function. Hearts were decellularized by coro-
nary perfusion with detergents, preserving the underlying
extracellular matrix, and producing an acellular, perfusable
vascular architecture, competent acellular valves, and intact
chamber geometry. To mimic cardiac cell composition, these
constructs were reseeded with cardiac or endothelial cells.
Constructs were maintained for up to 28 days by coronary
perfusion in a bioreactor that simulated cardiac physiology.
At day 4, macroscopic contractions were observed. At
day 8, under physiological load and electrical stimulation,
constructsgeneratedpumpfunction(equivalenttoabout2%
ofadultor25%of16-weekfetalheartfunction)inamodiﬁed
working heart preparation [47].
9.3. Ophthalmology. Corneal transplantation is a common
transplant procedure performed to improve visual acuity by
replacing the opaque or distorted host tissue by clear healthy
donor tissue. However, its clinical utility is limited due to
a lack of high-quality donor corneas. Bioengineered neo-
corneas, created using an expandable population of human
donor-derived corneal endothelial cells (HCECs), address
this current shortage. Studies were performed to investigate













Figure 1: (a) MAGNUM Clinical Trial: Ischemic heart disease patient, 3D representation of the preoperative radioisotopic SPECT Tc99m
sestamibi imaging, showing the chronic infarction area (blue stain). (b) Same patient, followup at 18 months showing the improvement of
myocardial viability and function (60% of reduction of the infarcted area, in blue) after stem cell therapy associated with the implantation
onto the infarct scar of a cell-seeded collagen matrix.
seeding the cells on decellularized human corneal stroma.
HCECs were removed from the discarded corneas of eye
donors by enzymatic digestion. Donor corneal stromas were
cut to 120–200microm thickness slices using a microtome
and then decellularized. To engineer neocorneas, HCECs
were seeded on decellularized human corneal stromas. The
resulting constructs were placed in growth medium for
14 days. Seeded cells retain expression of the functional
markers Na(+)/K(+)-ATPase and zona occludens ZO-1; in
addition, constructs demonstrated biomechanical properties
similar to those of normal corneas. These results indicate
that construction of neocorneas, using HCECs derived
from discarded donor corneas and decellularized thin-layer
corneal stromas, may create a new source of high-quality
corneal tissue for transplantation [48].
In summary, all these studies demonstrate a novel
yet simple and scalable method to obtain whole organ-
vascularized bioscaﬀolds with potential for liver, kidney,
heart, pancreas, intestine, and other organs’ bioengineering.
These bioscaﬀolds can further provide a tool to study cells
in their natural three-dimensional environment, which is
superior for drug discovery platform compared with cells
cultured in two-dimensional petridishes.
10.Bioengineered CardiacNanobiomaterials
Until now, the optimal cell-matrix combination for robust
and sustained myocardial restoration has not been iden-
tiﬁed. We are evaluating bioengineered nanobiomaterials
with polymer-based elastomeric membranes to obtain a
controlled drug release myocardium patch with additional
features, such as local cell attraction (proangiogenic activity)
and cell diﬀerentiation and delivery (precardiomyocytes).
Random injections of stem cells into the heart have proven
rather insuﬃcient due to poor cell retention and survival. In
ordertoengraft and functionmoreeﬀectively,bioengineered
tissues require some degree of early vascularisation. Hence,
more evolved tissue constructs must be produced involving
more eﬃcient vascularisation strategies.
Our group is developing a bioengineered platform
consisting in obtaining preconditioned electrostimulated
stem cells to resist their implantation into a highly stressed
tissue [49]. Cells are incorporated in this newly designed
biodegradable scaﬀolds that will support cell survival,
proper cardiomyogenic diﬀerentiation, and early extracellu-
lar instruction. This construct should induce vascularisation
to ensure rapid tissue remodelling and regeneration into a
newly functional myocardium.
Good progress in the design and fabrication of syn-
thetic biomaterials with biomimetic characteristics has been
accomplished in the ﬁeld of nanotechnology for direct
applications in biomedicine. The main purpose of these
materials is to display structural and functional properties
similar to extracellular matrices, containing truly three-
dimensional nanonetworks and eventual control in the
delivery and eﬀective concentration of “therapeutic drugs”
[50–52].
Nanomaterials are emerging as the main candidates to
ensure the achievement of a proper instructive cellular niche
with good drug release/administration properties. Synthetic
nanomaterials are attractive platforms because of their pure
composition, predictive toxicology, target speciﬁcity, low
manufacturing costs, and control in degradability. Proteins,
peptides, and polysaccharides are top on the list for their
versatility in nanomaterial design and fabrication [53, 54].
Investigating theelectrophysiologicalpropertiesofbioar-
tiﬁcial myocardium is the challenging objective of future
research. A multielectrode network to provide electrical
stimulation could be included in order to improve the
coupling of grafted stem cells and scaﬀolds with host car-
diomyocytes, the goal being to improve the local properties
of ischemic myocardium. In summary, until now stem
cell transplantation has not achieved clear hemodynamic
beneﬁts for myocardial diseases [55]. Supported by relevant
scientiﬁc background, the development of myocardial tissue
engineering may constitute a new avenue and hope for the
treatment of myocardial diseases [56, 57].6 Cardiology Research and Practice
References
[1] M. Jessup and S. Brozena, “Heart failure,” The New England
Journal of Medicine, vol. 348, no. 20, pp. 2007–2018, 2003.
[2] G. S. Bleumink, A. M. Knetsch, M. C. J. M. Sturkenboom
et al., “Quantifying the heart failure epidemic: prevalence,
incidence rate, lifetime risk and prognosis of heart failure—
the Rotterdam Study,” European Heart Journal, vol. 25, no. 18,
pp. 1614–1619, 2004.
[ 3 ]J .C .C h a c h q u e s ,A .S h a f y ,F .D u a r t ee ta l . ,“ F r o md y n a m i ct o
cellular cardiomyoplasty,” Journal of Cardiac Surgery, vol. 17,
no. 3, pp. 194–200, 2002.
[4] J.C. Chachques,C. Acar, J.Herreros et al.,“Cellularcardiomy-
oplasty: clinical application,” Annals of Thoracic Surgery,v o l .
77, no. 3, pp. 1121–1130, 2004.
[5] M. A. Pfeﬀer and E. Braunwald, “Ventricular remodeling after
myocardial infarction: experimental observations and clinical
implications,”Circulation, vol. 81, no. 4, pp. 1161–1172, 1990.
[ 6 ]J .S .W a n g ,D .S h u m - T i m ,J .G a l i p e a u ,E .C h e d r a w y ,N .
Eliopoulos, and R. C. J. Chiu, “Marrow stromal cells for
cellular cardiomyoplasty: feasibility and potential clinical
advantages,” Journal of Thoracic and Cardiovascular Surgery,
vol. 120, no. 5, pp. 999–1006, 2000.
[7] D. Orlic, J. Kajstura, S. Chimenti et al., “Mobilized bone
marrow cells repair the infarcted heart, improving function
and survival,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 98, no. 18, pp. 10344–
10349, 2001.
[8] D. A. Taylor, B. Z. Atkins, P. Hungspreugs et al., “Regenerating
functional myocardium: improved performance after skeletal
myoblast transplantation,” Nature Medicine,v o l .4 ,n o .8 ,p p .
929–933, 1998.
[ 9 ]C .R a j n o c h ,J .C .C h a c h q u e s ,A .B e r r e b i ,P .B r u n e v a l ,M .O .
Benoit, and A. Carpentier, “Cellular therapy reverses myocar-
dial dysfunction,” Journal of Thoracic and Cardiovascular
Surgery, vol. 121, no. 5, pp. 871–878, 2001.
[10] C. M. Verfaillie, R. Schwartz, M. Reyes, and Y. Jiang, “Unex-
pected potential of adult stem cells,” Annals of the New York
Academy of Sciences, vol. 996, pp. 231–234, 2003.
[11] J. C. Chachques, B. Cattadori, J. Herreros et al., “Treatment of
heartfailurewithautologousskeletalmyoblasts,”Herz,vol.27,
no. 7, pp. 570–578, 2002.
[ 1 2 ]H .K .H a i d e r ,A .C .K .T a n ,S .A z i z ,J .C .C h a c h q u e s ,a n dE .K .
W.Sim,“Myoblasttransplantationforcardiacrepair: aclinical
perspective,” Molecular Therapy, vol. 9, no. 1, pp. 14–23, 2004.
[ 1 3 ] F .V i l a s - B o a s ,G .S .F e i t o s a ,M .B .P .S o a r e se ta l . ,“ E a r l yr e s u l t s
of bone marrow cell transplantation to the myocardium of
patients with heart failure due to chagas disease,” Arquivos
Brasileiros de Cardiologia, vol. 87, no. 2, pp. 159–166, 2006.
[14] E.C.Perin,H.F.R.Dohmann,R.Borojevicetal.,“Transendo-
cardial, autologous bone marrow cell transplantation for
severe, chronic ischemic heart failure,” Circulation, vol. 107,
no. 18, pp. 2294–2302, 2003.
[15] J. C. Chachques, J. Herreros, J. Trainini et al., “Autologous
human serum for cell culture avoids the implantation of
cardioverter-deﬁbrillators in cellular cardiomyoplasty,” Inter-
national Journal of Cardiology, vol. 95, no. 1, pp. S29–S33,
2004.
[16] C. Stamm,B. Westphal, H. D. Kleine et al., “Autologous bone-
marrow stem-cell transplantation for myocardial regenera-
tion,” The Lancet, vol. 361, no. 9351, pp. 45–46, 2003.
[17] V. Sch¨ a c h i n g e r ,B .A s s m u s ,M .B .B r i t t e ne ta l . ,“ T r a n s -
plantation of progenitor cells and regeneration enhancement
in acute myocardial infarction: ﬁnal one-year results of the
TOPCARE-AMI trial,” Journal of the American College of
Cardiology, vol. 44, no. 8, pp. 1690–1699, 2004.
[18] D. A. Narmoneva, R. Vukmirovic, M. E. Davis, R. D. Kamm,
and R. T. Lee, “Endothelial cells promote cardiac myocyte
survival and spatial reorganization: implications for cardiac
regeneration,” Circulation, vol. 110, no. 8, pp. 962–968, 2004.
[19] B. Bourahla, A. Shafy, O. Meilhac, I. Elmadbouh, J. B. Michel,
a n dJ .C .C h a c h q u e s ,“ M e s o t h e l i a lc e l l sv s .s k e l e t a lm y o b l a s t s
for myocardial infarction,” Asian Cardiovascular and Thoracic
Annals, vol. 18, no. 2, pp. 153–160, 2010.
[20] V. Planat-B´ enard, C. Menard, M. Andr´ e et al., “Spontaneous
cardiomyocyte diﬀerentiation from adipose tissue stroma
cells,” Circulation Research, vol. 94, no. 2, pp. 223–229, 2004.
[21] I. Kehat, L. Khimovich, O. Caspi et al., “Electromechanical
integration of cardiomyocytes derived from human embry-
onic stem cells,” Nature Biotechnology, vol. 22, no. 10, pp.
1282–1289, 2004.
[ 2 2 ]M .C o r t e s - M o r i c h e t t i ,G .F r a t i ,O .S c h u s s l e re ta l . ,“ A s s o -
ciation between a cell-seeded collagen matrix and cellular
cardiomyoplasty for myocardial support and regeneration,”
Tissue Engineering, vol. 13, no. 11, pp. 2681–2687, 2007.
[23] I. Kutschka, I. Y. Chen, T. Koﬁdis et al., “Collagen matrices
enhance survival of transplanted cardiomyoblasts and con-
tribute to functional improvement of ischemic rat hearts,”
Circulation, vol. 114, no. 1, pp. I167–I173, 2006.
[24] O. Schussler, C. Coirault, M. Louis-Tisserand et al., “Use of
arginine-glycine-aspartic acid adhesion peptides coupled with
a new collagen scaﬀold to engineer a myocardium-like tissue
graft,” Nature Clinical Practice Cardiovascular Medicine,v o l .6 ,
no. 3, pp. 240–249, 2009.
[25] T. Eschenhagen and W. H. Zimmermann, “Engineering
myocardial tissue,” Circulation Research, vol. 97, no. 12, pp.
1220–1231, 2005.
[26] T. Koﬁdis, P. Akhyari, J.Boublik et al.,“In vitro engineering of
heart muscle: artiﬁcial myocardial tissue,” Journal of Thoracic
and Cardiovascular Surgery, vol. 124, no. 1, pp. 63–69, 2002.
[27] J. Leor and S. Cohen, “Myocardial tissue engineering: creating
a muscle patch for a wounded heart,” Annals of the New York
Academy of Sciences, vol. 1015, pp. 312–319, 2004.
[28] J. C. Chachques, J. C. Trainini, N. Lago,M. Cortes-Morichetti,
O. Schussler, and A. Carpentier, “Myocardial assistance by
grafting a new bioartiﬁcial upgraded myocardium (MAG-
NUM trial): clinical feasibility study,” Annals of Thoracic
Surgery, vol. 85, no. 3, pp. 901–908, 2008.
[29] C. Spadaccio, E. Chachques, M. Chello, E. Covino, J. C.
Chachques, and J. Genovese, “Prediﬀerentiated adult stem
cells and matrices for cardiac cell therapy,” Asian Cardiovas-
cular and Thoracic Annals, vol. 18, no. 1, pp. 79–87, 2010.
[30] K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of
pluripotent stemcellsfromadulthumanﬁbroblastsbydeﬁned
factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
[ 3 1 ] J .J .G a v i r a ,E .N a s a r r e ,G .A b i z a n d ae ta l . ,“ R e p e a t e d
implantation of skeletal myoblast in a swine model of chronic
myocardial infarction,” European Heart Journal, vol. 31, no. 8,
pp. 1013–1021, 2010.
[32] J. C. Chachques, A. Azarine, E. Mousseaux, M. El Seraﬁ,
M. Cortes-Morichetti, and A. F. Carpentier, “MRI evaluation
of local myocardial treatments: epicardial versus endocardial
(Cell-Fix catheter) injections,” Journal of Interventional Cardi-
ology, vol. 20, no. 3, pp. 188–196, 2007.
[33] T. Fink, L. Abildtrup, K. Fogd et al., “Induction of adipocyte-
likephenotypeinhumanmesenchymalstemcellsby hypoxia,”
Stem Cells, vol. 22, no. 7, pp. 1346–1355, 2004.Cardiology Research and Practice 7
[34] X. Hu, S. P. Yu, J. L. Fraser et al., “Transplantation of hypoxia-
preconditioned mesenchymal stem cells improves infarcted
heart function via enhanced survival of implanted cells and
angiogenesis,” Journal of Thoracic and Cardiovascular Surgery,
vol. 135, no. 4, pp. 799–808, 2008.
[ 3 5 ]W .D a i ,S .L .H a l e ,G .L .K a y ,A .J .J y r a l a ,a n dR .A .K l o n e r ,
“Delivering stem cells to the heart in a collagenmatrix reduces
relocation of cells to other organs as assessed by nanoparticle
technology,” Regenerative Medicine, vol. 4, no. 3, pp. 387–395,
2009.
[36] M. B¨ ohm, K. Swedberg, M. Komajda et al., “Heart rate as a
risk factor in chronic heart failure (SHIFT): the association
between heart rate and outcomes in a randomised placebo-
controlled trial,” The Lancet, vol. 376, no. 9744, pp. 886–894,
2010.
[37] A. Carpentier, J. C. Chachques, and P. Grandjean, Eds.,
Cardiac Bioassist, Futura Publishing, New York, NY, USA,
1997.
[38] J. C. Chachques, P. G. Argyriadis, G. Fontaine et al., “Right
ventricular cardiomyoplasty: 10-year follow-up,” Annals of
Thoracic Surgery, vol. 75, no. 5, pp. 1464–1468, 2003.
[39] L. W. Stevenson, L. W. Miller, P. Desvigne-Nickens et al.,
“Left ventricular assist device as destination for patients
undergoing intravenous inotropic therapy: a subset analysis
from REMATCH (Randomized Evaluation of Mechanical
Assistance in Treatment of Chronic Heart Failure),” Circula-
tion, vol. 110, no. 8, pp. 975–981, 2004.
[40] L. Cui, J. Jiang, L. Wei et al., “Transplantation of embryonic
stem cells improves nerve repair and functional recovery after
severe sciatic nerve axotomy in rats,” Stem Cells, vol. 26, no. 5,
pp. 1356–1365, 2008.
[41] R. Soler, C. Fullhase, and A. Atala, “Regenerative medicine
strategies for treatment of neurogenic bladder,” Therapy,v o l .
6, no. 2, pp. 177–184, 2009.
[42] J. C. Chachques, F. Duarte, B. Cattadori et al., “Angio-
genic growth factors and/or cellular therapy for myocardial
regeneration: a comparative study,” Journal of Thoracic and
Cardiovascular Surgery, vol. 128, no. 2, pp. 245–253, 2004.
[43] D. W. Losordo and S. Dimmeler, “Therapeutic angiogenesis
and vasculogenesis for ischemic disease: part I: angiogenic
cytokines,” Circulation, vol. 109, no. 21, pp. 2487–2491, 2004.
[44] K.A.T .Carvalho ,L.C.G uarita-Souza,C.L.K.R ebelatt oetal.,
“Could the coculture of skeletal myoblasts and mesenchymal
stem cells be a solution for postinfarction myocardial scar?”
Transplantation Proceedings, vol. 36, no. 4, pp. 991–992, 2004.
[45] A. Shafy, T. Lavergne, C. Latremouille, M. Cortes-Morichetti,
A. Carpentier, and J. C. Chachques, “Association of electros-
timulationwithcell transplantationinischemicheart disease,”
Journal of Thoracic and Cardiovascular Surgery, vol. 138, no. 4,
pp. 994–1001, 2009.
[ 4 6 ] P .M .B a p t i s t a ,G .O r l a n d o ,S .H .M i r m a l e k - S a n i ,M .S i d d i q u i ,
A. Atala, and S. Soker, “Whole organ decellularization—a
tool for bioscaﬀold fabrication and organ bioengineering,” in
Proceedings of the 31st Annual International Conference of the
IEEE Engineering in Medicine and Biology Society (EMBC ’09),
pp. 6526–6529, September 2009.
[47] H. C. Ott, T. S. Matthiesen, S. K. Goh et al., “Perfusion-
decellularized matrix: using nature’s platform to engineer a
bioartiﬁcial heart,” Nature Medicine, vol. 14, no. 2, pp. 213–
221, 2008.
[48] J. S. Choi, J. K. Williams, M. Greven et al., “Bioengineer-
ing endothelialized neo-corneas using donor-derived corneal
endothelial cells and decellularized corneal stroma,” Biomate-
rials, vol. 31, no. 26, pp. 6738–6745, 2010.
[ 4 9 ]J .A .G e n o v e s e ,C .S p a d a c c i o ,E .C h a c h q u e se ta l . ,“ C a r d i a c
pre-diﬀerentiation of human mesenchymal stem cells by
electrostimulation,” Frontiers in Bioscience, vol. 14, pp. 2996–
3002, 2009.
[50] S. Chen, S. Hilcove, and S. Ding, “Exploring stem cell biology
with small molecules,” Molecular BioSystems,v o l .2 ,n o .1 ,p p .
18–24, 2006.
[51] C. E. Semino, “Can we build artiﬁcial stem cell compart-
ments?” Journal of Biomedicine and Biotechnology,v o l .3 ,p p .
164–169, 2003.
[52] J. C. Rodr´ ıguez Hern´ andez, M. S. S´ a n c h e z ,J .M .S o r i a ,J .
L. G´ omez Ribelles, and M. M. Pradas, “Substrate chemistry-
dependent conformations of single laminin molecules on
polymer surfaces are revealed by the phase signal of atomic
force microscopy,” Biophysical Journal, vol. 93, no. 1, pp. 202–
207, 2007.
[53] E. Genov´ e, C. Shen, S. Zhang, and C. E. Semino, “The eﬀect
of functionalized self-assembling peptide scaﬀolds on human
aortic endothelial cell function,” Biomaterials, vol. 26, no. 16,
pp. 3341–3351, 2005.
[54] J. C. Rodr´ ıguez Hern´ andez, A. Serrano Aroca, J. L. G´ omez
Ribelles, and M. Monle´ on Pradas, “Three-dimensional
nanocomposite scaﬀolds with ordered cylindrical orthogonal
pores,” Journal of Biomedical Materials Research PartB, vol.84,
no. 2, pp. 541–549, 2008.
[55] S. N. Zhang, A. J. Sun, J. B. Ge et al., “Intracoronary
autologous bone marrow stem cells transfer for patients with
acute myocardial infarction: a meta-analysis of randomised
controlled trials,” International Journal of Cardiology, vol. 136,
no. 2, pp. 178–185, 2009.
[56] E. C. Martinez and T. Koﬁdis, “Myocardial tissue engineering:
the quest for the ideal myocardial substitute,” Expert Review of
Cardiovascular Therapy, vol. 7, no. 8, pp. 921–928, 2009.
[57] J. C. Chachques, “Cellular cardiac regenerative therapy in
which patients?” Expert Review of Cardiovascular Therapy,v o l .
7, no. 8, pp. 911–919, 2009.